Personalized Diagnostics Is Dynamic Area of IVD Sector

Diagnostic tests that can direct a therapy to a specific patient, or segment of the population, to improve outcomes and lower costs, are experiencing faster sales growth.

A detailed account by Kalorama Information (New York, NY, USA), the healthcare market research publisher, tracks sales of personalized medicine tests, reporting growth falling between 7% and 38% per year, compared with the more moderate 2%-6% growth of in vitro diagnostics (IVD) generally.

Personalized tests such as fluorescent in situ hybridization (FISH) for cancer screening, CYP450 tests for psychiatric therapy, individual microbiologic assessments to treat infectious disease, and tissue transplant typing, rose to USD 28.1 billion in 2011.

Kalorama's market estimate covers tests that can also provide therapy decision-making information that is tailored to the individual, which falls into four categories: tests that identify a population in which the therapeutic product will achieve greater (or little) effectiveness, tests that identify a patient population that should not receive a particular therapeutic product, tests that identify the characteristics of a disease, and tests that are the basis for selecting a safe and efficacious therapeutic dose.

In the full study, Kalorama Information defines the current opportunity and realistic future potential of personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the report profiles key competitors and discusses trends that are important for understanding this growth area of the diagnostic industry. It also profiles scores of companies that are involved in making tests for this market.

A special focus of the report is the collaborations between IVD and pharmaceutical companies, as well as IVD companies and Clinical Laboratory Improvement Amendments (CLIA) labs.

Kalorama Information, a division of MarketResearch dot com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare; as well as a full range of custom research services.

Related Links:
Kalorama Information